Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
October 22, 2014 1:27 PM EDT
RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $375. Analyst Michael J. Yee commented on today's decline, linking it to light Tecfidera results. He also tied the fall in part to the disclosure of a PML case for Tecfidera. After 4.5 years of... More
October 22, 2014 12:45 PM EDT
Baird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
...
More
October 22, 2014 10:52 AM EDT
Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.
"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More
